Supernus Pharmaceuticals ... (SUPN)
NASDAQ: SUPN
· Real-Time Price · USD
32.45
0.06 (0.19%)
At close: May 06, 2025, 3:59 PM
32.28
-0.52%
Pre-market: May 07, 2025, 04:43 AM EDT
0.19% (1D)
| Bid | 30 |
| Market Cap | 1.82B |
| Revenue (ttm) | 661.82M |
| Net Income (ttm) | 73.86M |
| EPS (ttm) | 1.32 |
| PE Ratio (ttm) | 24.58 |
| Forward PE | 12.78 |
| Analyst | Hold |
| Ask | 33.27 |
| Volume | 595,211 |
| Avg. Volume (20D) | 621,723 |
| Open | 32.37 |
| Previous Close | 32.39 |
| Day's Range | 31.70 - 32.78 |
| 52-Week Range | 25.53 - 40.28 |
| Beta | 0.74 |
About SUPN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SUPN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SUPN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsEarnings Surprise
Supernus Pharmaceuticals has released their quartely earnings
on May 6, 2025:
2 months ago
-15.67%
Supernus Pharmaceuticals shares are trading lower ...
Unlock content with
Pro Subscription
2 months ago
+1.64%
Supernus Pharmaceuticals shares are trading lower after the company announced that the Phase 2b study of SPN-820 in adults with treatment-resistant depression did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale.
